pone.0298596.g001.tif (747.61 kB)
IRs per 100 person-years of safety outcomes associated with first use of rivaroxaban and VKAs for the treatment and secondary prevention of VTE.
figure
posted on 2024-03-07, 18:34 authored by Ana Ruigómez, Tania Schink, Annemarie Voss, Ron M. C. Herings, Elisabeth Smits, Karin Swart-Polinder, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis Alberto García RodríguezCI, confidence interval; IR, incidence rate; Riva, rivaroxaban; VKA, vitamin K antagonist; VTE, venous thromboembolism.
History
Usage metrics
Categories
Keywords
vitamin k antagonistsvitamin k antagonistroutine clinical practicerecent cancer history9 &# 8211time users treatedbleeding ), deatheuropean rivaroxaban post44 737 rivaroxabanxlink "> overallxlink "> cohortsamong rivaroxaban userscrude incidence ratesdecember 2017 ).venous thromboembolism indicationxlink ">rivaroxaban usersvenous thromboembolismincidence ratesdecember 2017vte indicationdecember 2018december 2016december 2011study providesstudy endsecondary preventionsafety profilesafety outcomerenal impairmentjanuary 2012gastrointestinal bleedingcomplement findingsatrial fibrillation
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC